If you prescribe or monitor Tysabri in Texas, you know PML is a rare but serious concern. For decades, pharmacovigilance research has documented the link between natalizumab and progressive multifocal leukoencephalopathy, shaping current risk-mitigation strategies. This page addresses key clinical questions about PML monitoring, diagnosis, and management for Texas clinicians.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn’s disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Texas who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits for filing a claim is critical. PML is an infection of the brain’s white matter that typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three key risk factors have been identified: the presence of anti-JCV antibodies in the blood, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinically, PML presents with progressive neurological deficits such as weakness, vision changes, speech difficulties, and cognitive decline. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri works by binding to alpha-4 integrin on immune cells, preventing their migration into the central nervous system. This reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus. In the setting of reduced immune cell trafficking, latent JC virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The mechanistic link is well established: Tysabri’s immunomodulatory effect creates an environment permissive for JC virus replication in the brain. The FDA has required a boxed warning on Tysabri’s label since its reintroduction to the market in 2006. The warning states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also instructs that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients and physicians may not fully appreciate the magnitude of risk, particularly in those with multiple risk factors. The adequacy of warnings is a central issue in litigation, as plaintiffs may argue that the label did not sufficiently communicate the risk or that the manufacturer failed to update warnings as new data emerged.
Patients who develop PML after Tysabri treatment may be eligible for compensation through settlement or litigation. Key considerations include the severity of injury, the presence of risk factors, and the timeline of exposure and diagnosis. The manufacturer, Biogen, has established a restricted distribution program called the TOUCH Prescribing Program to manage the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, healthcare providers must evaluate patients at specified intervals and report cases of PML to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Failure to adhere to monitoring protocols may affect liability. In Texas, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, the date of discovery is typically when a physician makes the diagnosis or when symptoms become clearly attributable to the drug. Because PML can develop insidiously, the clock may start later if the patient was unaware of the link. However, Texas law also recognizes a “discovery rule” that can extend the deadline if the injury was inherently undiscoverable. Patients should consult with a Texas attorney experienced in pharmaceutical litigation to determine the exact deadline for their case. PML typically occurs after prolonged Tysabri exposure, with risk increasing significantly after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The latency period from JC virus reactivation to clinical symptoms can range from weeks to months. Once symptoms appear, diagnosis may be delayed if PML is not immediately suspected. This timeline is critical for statute of limitations calculations, as the injury may not be “discovered” until a definitive diagnosis is made.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Texas, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, the date of discovery is typically when a physician makes the diagnosis or when symptoms become clearly attributable to the drug. Because PML can develop insidiously, the clock may start later if the patient was unaware of the link. Texas law also recognizes a “discovery rule” that can extend the deadline if the injury was inherently undiscoverable. Patients should consult with a Texas attorney experienced in pharmaceutical litigation to determine the exact deadline for their case.
Three key risk factors have been identified: the presence of anti-JCV antibodies in the blood, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.